Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $745.46K rose 0.3% year over year, ahead of the -3.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 1.1% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.
Context
- Depreciation & amortization amounted to 4574.1% of revenue in FY2025, up 3136.7 pp from a year earlier.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.3% holds above the trailing-twelve-month pace of -3.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 2.99M USD
- Year-over-year change
- -4.5%
- 4-year CAGR
- -10.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.99M | -4.5% |
| FY2024 | 2024-12-31 | 3.13M | -10.7% |
| FY2023 | 2023-12-31 | 3.5M | -36.3% |
| FY2022 | 2022-12-31 | 5.5M | +16.2% |
| FY2021 | 2021-12-31 | 4.73M | — |
Depreciation & Amortization vs competitors
How INO compares with its peers on the latest reported figures
- INO's LTM Mar 2026 depreciation & amortization of $2.99M is the 6th highest of the 10 companies compared; the peer median is $5.03M.
- Its year-over-year change of -3.9% is the 6th highest of 10, against a peer median of -3.9%.
- Over three fiscal years its annual growth of -18.4% compares with a peer median of +2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $12.49M | -28.5% | -12.3% | 197.7% | |
| LTM Mar 2026 | $8.8M | +4.8% | +4.5% | 47.8% | |
| LTM Mar 2026 | $7.38M | -44.0% | +12.9% | 6.0% | |
| LTM Mar 2026 | $6.03M | -3.9% | +1.1% | 40.1% | |
| LTM Mar 2026 | $5.03M | +1.0% | -14.6% | 438.9% | |
| LTM Mar 2026 | $2.99M | -3.9% | -18.4% | — | |
| LTM Mar 2026 | $185K | +3.4% | +2.9% | — | |
IRDOpus Genetics, Inc. | LTM Mar 2026 | $53K | +241.9% | +136.6% | 0.4% |
| LTM Mar 2026 | $1K | -71.4% | — | 0.0% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | $0 | -100.0% | — | — |
| Peer median (excluding INO) | $5.03M | -3.9% | +2.9% | 40.1% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 1.77M | 10.26M | 832.01K | 217.76K | 65.34K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 249.24M | 187.65M | 86.68M | 75.62M | 54.21M |
| Selling, General & Admin | 53.75M | 90.19M | 47.58M | 37M | 32.68M |
| Operating Expenses | 302.99M | 277.84M | 144.77M | 112.62M | 86.89M |
| Depreciation & Amortization | 4.73M | 5.5M | 3.5M | 3.13M | 2.99M |
| EBITDA | (296.56M) | (270.9M) | (130.39M) | (103.95M) | (81.96M) |
| EBITDA Margin | -16709.7% | -2639.8% | -15671.8% | -47735.2% | -125425.9% |
| Operating Income | (301.22M) | (267.57M) | (143.94M) | (112.4M) | (86.82M) |
| Operating Margin | -16972.3% | -2607.4% | -17300.3% | -51616.9% | -132871.3% |
| Interest Income | 3.36M | 4.78M | 8.13M | 4.77M | 2.42M |
| Interest Expense | 1.94M | 1.25M | 1.22M | 177.83K | 0 |
| Other Income / Expenses | (2.44M) | (12.24M) | 8.82M | 5.14M | 1.88M |
| Income Before Tax | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Pre-Tax Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (303.66M) | (279.82M) | (135.12M) | (107.25M) | (84.95M) |
| Net Margin | -17109.9% | -2726.7% | -16239.9% | -49254.3% | -130000.0% |
| EPS (Basic) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| EPS (Diluted) | (1.42) | (14.07) | (6.09) | (3.95) | (1.81) |
| Weighted Avg Shares | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
| Weighted Avg Shares (Diluted) | 214.62M | 19.89M | 22.17M | 27.16M | 468.86M |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.